Dolutegravir As First- or Second-Line Treatment for HIV-1 Infection in Children.
A. Turkova,E. White,H. A. Mujuru,A. R. Kekitiinwa,C. M. Kityo,A. Violari,A. Lugemwa,T. R. Cressey,P. Musoke,E. Variava,M. F. Cotton,M. Archary,T. Puthanakit,O. Behuhuma,R. Kobbe,S. B. Welch,M. Bwakura-Dangarembizi,P. Amuge,E. Kaudha,L. Barlow-Mosha,S. Makumbi,N. Ramsagar,C. Ngampiyaskul,G. Musoro,L. Atwine,A. Liberty,V Musiime,D. Bbuye,G. M. Ahimbisibwe,S. Chalermpantmetagul,S. Ali,T. Sarfati,B. Wynne,C. Shakeshaft,A. Colbers,N. Klein,S. Bernays,Y. Saidi,A. Coelho, T. Grossele,A. Compagnucci,C. Giaquinto,P. Rojo, DFord,D. M. Gibb New England Journal of Medicine（2021）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper